Background: Concomitant diabetes mellitus (DM) in atrial fibrillation (AF) may increase the risk of thromboembolism. Left atrial appendage occlusion (LAAO) is an alternative treatment in AF patients in whom antithrombotic therapy is ineffective or contraindicated. The aim of this study was to evaluate the long-term efficacy of LAAO in DM patients with AF. Methods: A retrospective study was conducted in 139 patients who had undergone LAAO and were categorized into two groups: 28 patients with DM and 111 patients without DM. Overall, the follow-up period was 530 patientyears. Results: Mean CHADS 2 and CHA 2 DS 2 -VASc scores were higher in patients with than without DM (2.6 vs 1.7 [P < 0.001] and 3.5 vs 2.8 [P = 0.056], respectively). There were no significant differences between the two groups in terms of HAS-BLED scores and other patient factors (sex, age, heart failure, hypertension, previous stroke or transient ischemic attack, peripheral vascular disease) that may increase the risk of thromboembolism based on CHA 2 DS 2 -VASc. The mean follow-up period was 51.6 and 50 months in patients with DM and without DM, respectively. Comparing patients with and without DM, there were no significant differences in thromboembolic events (4% vs 1.9%), severe bleeding (0% vs 3.1%), or mortality (4% vs 5.9%). The estimated reductions in thromboembolic and bleeding risk were 77% and 100%, respectively, for patients with DM, compared with 85% and 62%, respectively, for patients without DM. Conclusion: The present study indicates that LAAO in AF patients with DM has similar safety endpoints and long-term efficacy as LAAO in patients without DM.
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke approximately fivefold. 1 The prevalence of AF increases markedly with diabetes mellitus (DM): almost 15% of patients with DM have AF, 2 and nearly one in five patients with AF have concomitant DM. 3 Moreover, the prevalence of AF and DM will increase worldwide: AF due to an aging population, 4 and DM due to lifestyle changes leading to obesity. 5 Patients with AF and diabetes have an increased risk of stroke and a firm indication for oral anticoagulation (OAC). Diabetes mellitus increases the CHA 2 DS 2 -VASc score (1 point for: congestive heart failure, hypertension, age ≥ 75 years [doubled] , diabetes mellitus, prior stroke or transient ischemic attack [doubled] , vascular disease, age 65-74 years, female), therefore all patients with DM should be considered for OAC. 6 However, in nearly 40% of patients with AF, OAC is contraindicated. 7 Moreover, DM patients taking non-vitamin K oral anticoagulants have a greater absolute thromboembolic risk reduction, but also an increased risk of bleeding. 8 The longer the duration of DM in patients with AF, the greater the risk of thromboembolism. 9 Left atrial appendage occlusion (LAAO) is a mechanical therapy for the prevention of stroke and thromboembolism in high-risk patients with AF. Currently, LAAO procedures are widely performed in clinical practice. To date, the use of LAAO in diabetic patients has not been investigated. Herein, we describe longterm results of LAAO in patients with AF and DM.
Methods
A retrospective single-center study was performed in 139 consecutive patients with non-valvular AF who underwent LAAO with the Lariat device (SentreHEART, Redwood, CA, USA) between December 2009 and January 2012.
For the purposes of the study, the cohort was divided into two groups: patients with DM and patients without DM. Data collected included patient demographics, medical histories, and left atrial appendage (LAA) dimensions. Post-procedure anticoagulation and changes to anticoagulant therapy was individualized depending on a patient's history, contraindications, risk of stroke and bleeding, and the preferences of the patients and physicians.
To evaluate the presence of post-procedure leak, transesophageal echocardiography was performed at 30 days follow-up. Leaks (defined as the presence of flow from the left atrium to the LAA) were categorized as either a complete or <1-mm leak, a <2-mm leak, or a <3-mm leak.
Adverse events reported during follow-up visits, based on the Munich consensus document, 10 included mortality (cardiovascular, non-cardiovascular, procedural mortality, immediate procedural mortality), thromboembolic events (stroke, transient ischemic attack [TIA] , systemic embolism) and bleeding (lifethreating or disabling, major bleeding, minor bleeding). Procedure efficacy to prevent thromboembolic events (stroke, TIA, systemic embolism, thrombus in the heart chamber) was also evaluated by comparing the actual event rate at follow-up with the event rate predicted by the CHA 2 DS 2 -VASc score. 4 The annual risk was recorded for individual patients, and the average annual risk for the entire study population was calculated. To obtain the actual annual rate of thromboembolic events, the total number of thromboembolic events during the overall follow-up period was divided by the total patient years of follow-up and multiplied by 100. Thromboembolism reduction was calculated as (estimated percentage event rateactual percentage event rate)/(estimated percentage event rate).
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Bleeding reduction was assessed using the same method as for stroke reduction. The total number of major bleeding events per year was compared with the number of events predicted by the HAS-BLED score (1 point for hypertension, abnormal renal/liver function, stroke, bleeding, labile international normalized ratios [INRs] , elderly, drugs and alcohol), 12 and bleeding reduction was calculated as (estimated percentage event rate -actual percentage event rate)/(estimated percentage event rate).
Ethics approval and consent to participate in the study All patients were fully informed about the study procedure and provided written informed consent. The study protocol was approved by the Polish Ministry of Health and the Ethics Committee at John Paul II Hospital (Krakow, Poland). The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
Statistical analysis
Continuous variables were analyzed for normal distribution using the Shapiro-Wilk test. Unless otherwise stated, data are expressed as the mean AE SD or as median values with the interquartile range (IQR). If a non-parametric test was used, the data were additionally presented as the mean AE SD for better comparison with other studies. To assess the differences between two continuous variables, Student's t-test (for normally distributed values) or the Mann-Whitney U-test (for non-normally distributed values) was used. Categorical variables are expressed as counts and percentages. Baseline characteristics between groups were compared using a t-test for continuous variables and a Chisquared test for categorical variables. Kaplan-Meier analysis was performed to estimate survival over time. Statistical analyses were performed using STATISTICA 10.0 (StatSoft, Tulsa, OK, USA). Two-sided P < 0.05 was considered significant.
Results
In all, LAAO was performed in 139 patients: 28 with DM and 111 without DM. Comparing patients with DM and those without DM revealed significant differences in thromboembolic risk based on the CHADS 2 score (1 point for congestive heart failure, hypertension, age ≥ 75 years, DM, prior stroke or TIA; 2.6 AE 0.9 vs 1.7 AE 1, respectively; P ≤ 0.001), and a tendency towards a significantly higher risk based on the CHA 2 DS 2 -VASc score (3.5 AE 1.6 vs. 2.8 AE 1.6, respectively; P = 0.056). There were no significant differences in bleeding risk based on the HAS-BLED score, the prevalence of chronic heart failure, previous stroke or TIA, coronary artery disease, hypertension, chronic obstructive pulmonary disease, antithrombotic treatment, or LAA dimensions. Baseline clinical and demographic characteristics of patients with and without DM are presented in Table 1 .
Results of periprocedural outcomes and after 1 year of follow-up in all patients have been reported previously. 13 Up to 1 year of follow-up there were two cardiovascular deaths unrelated to the procedure, two episodes of major bleeding, and no thromboembolic events. We include all these reported events in the analyses. There were no differences in the presence of postoperative leaks between the two groups.
One year after LAAO, 12 patients were lost to follow-up. The average follow-up period was 51.6 and 50 months in patients with DM and without DM, respectively. Overall, the accumulated followup period in the study population was 530.1 patientyears.
One ischemic stroke was observed in a patient with DM, and there were two thrombi in the LAA in patients without DM. There were no significant differences in post-procedure medications, mortality, or major bleeding between the two groups ( Table 2 ). In addition, survival analysis indicated no significant differences between patients with and without DM in during the overall follow-up in terms of thromboembolic events (Fig. 1) or death (Fig. 2) .
In patients with DM, the estimated annual thromboembolic event risk reduction was 77%, compared with 85% in patients without DM (Fig. 3) . The estimated severe bleeding risk reduction in patients with DM was 100%, compared with 62% in patients without DM (Fig. 4) . 
Discussion
The LAAO procedure in AF patients with DM reduces the risk of thromboembolic events and severe bleeding in the long term. The results of the present study indicate that the prevalence of thromboembolic events and the reduction in thromboembolic risk after LAAO are similar in patients with DM and without DM. To our knowledge, the present study is the first to assess LAAO in DM patients with long-term follow-up. The pathology of AF is multifactorial. The Framingham study showed that DM is an independent risk factor for AF with an odds ratio of 1.4 for men and 1.6 for women.
14 Because of the lifestyle of Western society, 
Figure 1
Kaplan-Meier curve for thromboembolic events (ischemic stroke, transient ischemic attack, thrombus, systolic embolism) in patients with and without type 2 diabetes mellitus (T2DM) during the overall follow-up period. 
Figure 2
Kaplan-Meier survival analysis in patients with and without type 2 diabetes mellitus (T2DM) during the overall follow-up period.
Figure 3
Effectiveness of stroke risk reduction (%) in patients with and without type 2 diabetes mellitus (T2DM) during the overall follow-up period.
it has been unambiguously shown that the number of new cases of AF and DM in the following years will increase markedly. 4, 5 Based on the CHA 2 DS 2 -VASc score, DM is a well-established independent risk factor for stroke and is associated with high mortality. Therefore, OAC treatment should be considered for patients with AF and concomitant DM. 6 However, OAC has several limitations: OAC is contraindicated in nearly 40% of patients, 7 in some patients adherence to therapy is challenging, 15 and there is a high percentage of complications, including severe bleeding, associated with OAC therapy and new OAC therapy. [16] [17] [18] Therefore, LAAO has become an attractive strategy for stroke prevention, 6 regardless of a patient's age. 19 The LAAO procedure may be performed using two different techniques: endocardial or epicardial. 20 Endocardial devices, like the Watchman (Boston Scientific, Natick, MA, USA) or the Amulet (St. Jude Medical, Plymouth, MN, USA) are self-expanding occluder delivered to the LAA via trans-septal puncture. After 6 weeks of implantation, complete epithelialization of the device surface is observed. 21, 22 Other techniques include epicardial approaches using a Lariat device (SentreHEART, Redwood, CA, USA) for epicardial ligation of the LAA with sutures, with leaves no foreign body implanted in the LAA. 20, 23 After epicardial exclusion, a significant inflammatory response is observed and the LAA is permanently closed. 24 Short-and longterm data have shown that both techniques are efficacious in reducing the risk of thromboembolism and stroke in a diverse group of patients in whom OAC is contraindicated. [19] [20] [21] [22] 25, 26 It should also be mentioned that there are substantial differences in hemodynamics and neurohormonal effects of LAA exclusion with epicardial LAA device. 27, 28 Lakkireddy et al. 28 found that, in a small group of patients, in contrast with endocardial devices, epicardial LAA exclusion increase lipolysis and insulin levels. However, these observations require further investigation in a larger group of patients.
Large trials, such as PROTECT AF (Left Atrial Appendage System for Embolic Protection in Patients with AF), 22 PROTECT AF CAP (Left Atrial Appendage System for Embolic Protection in Patients with AF Continued Access Registry), 29 Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO), 30 and PREVAIL (Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy), 21 have shown that DM is a risk factor for stroke in 22.4%-33.8% of patients who undergo endocardial LAAO. Similarly, in epicardial studies with the Lariat device, DM was observed in 18.9%-28% of patients. 26, 31 However, neither of these studies analyzed the results of LAAO in a subgroup of DM patients. In the present study, diabetes was present in 20.1% of patients, which is similar to rates reported in previous studies.
The results of the present study showed that the prevalence of thromboembolic events and the reduction in thromboembolic risk after LAAO was similar in both groups (Fig. 3) . One ischemic stroke was observed in a patient with DM, and there were two thrombi in the LAA, which were successfully resolved with unfractionated heparin with no further complications. An important finding of the study was that the risk of stroke, based on CHADS 2 score, was significantly higher (P < 0.001) in patients with DM. In addition, there was a trend towards higher risk of stroke in patients with DM based on CHA 2 DS 2 -VASc scores (P = 0.056). There were no differences in between patients with and without DM in terms of sex, age, vascular disease, heart failure, and history of thromboembolism, factors that increase the risk of thromboembolism events based on CHA 2 DS 2 -VASc scores 6 (Table 1) . Diabetes mellitus was the only risk factor that differed in both groups. Overvad et al. 9 found that in patients with AF, the longer the duration of DM, the greater the risk of thromboembolism. Overvad et al. 9 reported that during the first 4 years of diabetes in patients on OAC, the incidence of thromboembolism was 2.8. Due to the retrospective nature of the present study, we have no information of diabetes duration in our patient cohort. In the present study, after an average 4.2 years of follow-up, the incidence rate of thromboembolism was 0.9 (data not shown). Therefore, the difference between the expected and actual rate of thromboembolism could be even higher.
There were no differences in thromboembolic events between the two groups (Table 2 ). However, the Effectiveness of bleeding risk reduction (%) in patients with and without type 2 diabetes mellitus (T2DM) during the overall follow-up period.
estimated risk reduction of severe bleeding in patients with DM seemed to be higher than in patients without DM (Fig. 4) , even though the baseline HAS-BLED scores were similar in both groups. Of note, all observed severe bleeding events in this study were hemorrhagic strokes: 3 cases in patients on OAC therapy, and 1 case due to uncontrolled hypertension. The phenomenon of low-frequency hemorrhage in patients with diabetes is well known. 32, 33 However, the observed bleeding rates in patients with versus without diabetes are inconsistent. 34 In the study of Overvad et al., 9 during 4 years of diabetes in patients on OAC, the incidence rate of bleeding was 6.8, whereas in the present cohort of patients there were no episodes of severe bleeding. Overvad et al. 9 also found that indication of a lower bleeding risk with a longer duration of DM. In a study of patients with type 1 DM, the duration of DM was found to be a risk predictor for ischemic stroke, but not hemorrhagic stroke. 35 However, in the study of Overvad et al., 9 all patients received a vitamin K antagonist (VKA), whereas in the present patients received a variety of antithrombotic treatments, including VKA, new oral anticoagulants, and antiplatelet therapy. In addition, in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) study evaluating apixaban versus warfarin, diabetes was found to be a risk factor for major hemorrhage. 36 In contrast, in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study, 8 the ROCKET-AF (Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation) study, 37 and in metaanalyses, 38, 39 there was no correlation between patients with DM and an increased bleeding rate compared with the general population. It should be noted that there were no significant differences in antithrombotic treatment at the time of last follow-up between groups in the present study.
The safety, efficacy, and short-term results in the overall Lariat cohort from the John Paull II Hospital in Krakow have been published elsewhere. 13, 27, 40 There were no significant differences in cardiovascular and non-cardiovascular deaths upon long-term follow-up (Fig. 2) . There is some evidence that the association between AF and DM may significantly increase the risk of mortality. 41 However, large multicenter prospective studies have also shown no increase in mortality in the short term in AF patients with DM. 42 
Study limitations
Herein we present the results of a non-randomized retrospective observational single-center study. The major limitation for estimating the overall value of LAAO is the lack of a control group and using only a calculated stroke or bleeding risk score for analysis. Twelve patients were lost to follow-up after 1 year (8.6%). The number of patients in the two groups was unequal (28 with DM, 111 without DM). Long-term results for thromboembolic events and bleeding risk reduction may be confounded by the high and varied proportion of antithrombotic therapies at the time of last follow-up.
Conclusions
The results of the present study suggest that LAAO in AF patients with DM has similar safety endpoints and long-term efficacy as LAAO in the general population, and has similar stroke and bleeding prevention rates as in patients without DM.
